in the absence of a submission from the holder of the marketing authorisation:
vedolizumab (Entyvio®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice615KB (PDF)
Medicine details
- Medicine name:
- vedolizumab (Entyvio)
- SMC ID:
- SMC2506
- Indication:
Treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 July 2022